Effect of Green Tea on Stroke

The effect of powdered green tea enriched with epigallocatechin gallate (EGCG) on some clinical, biochemical, inflammatory, antioxidant and cognitive parameters in stroke patients; a double-blind, placebo-controlled clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180902040927N1

Enrollment

Registered

2018-10-04

Start date

2018-09-23

Completion date

Unknown

Last updated

2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke. Cerebellar stroke syndrome

Interventions

Intervention 1: Intervention group: To receive 60 mg capsules containing green tea powder with 40% effective epigallocatechin gallate twice daily. Intervention 2: Control group: To receive capsules c

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients have referred in the 1st day of the stroke Patients was 30 and 80 years old. Patients who have completed the Consent form. Patients with an ischemic stroke. Patients with supratentorial ischemic stroke

Exclusion criteria

Exclusion criteria: Patients with hemorrhagic stroke Patients with severe stroke (NIHSS> 25). Patients with lacunar and inferatentorial type of ischemic stroke . Patients received tPA. Patients who have secondary stroke due to autoimmune disorders such as lupus and autoimmune hemolytic anemia and other inflammatory diseases. stroke patients have Pregnant.

Design outcomes

Primary

Measure	Time frame
National Institutes of Health Stroke Scale. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: National Institutes of Health Stroke Scale.;Measurement index of stroke disability. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: Modified Rankin Scale.;Life Quality score. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: Based on the life quality questionnaire.;Brain-Derived Neurotrophic Factor. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: ELISA method.;Lipid profile. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: Auto analyzer.;Interleukin-10. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: ELISA method.;Tumor necrosis factor alpha. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: ELISA method.;Mini–Mental State Examination score. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: Mini–Mental State Examination.	—

Measure

Time frame

National Institutes of Health Stroke Scale. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: National Institutes of Health Stroke Scale.;Measurement index of stroke disability. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: Modified Rankin Scale.;Life Quality score. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: Based on the life quality questionnaire.;Brain-Derived Neurotrophic Factor. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: ELISA method.;Lipid profile. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: Auto analyzer.;Interleukin-10. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: ELISA method.;Tumor necrosis factor alpha. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: ELISA method.;Mini–Mental State Examination score. Timepoint: Before taking drug and after 3 months of taking drug. Method of measurement: Mini–Mental State Examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdieh Azin

Rafsanjan University of Medical Sciences

mahdieh.azin@gmail.com+98 34 3131 5079

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026